

Index

Note: Page numbers in *italics* refer to *figures*; those in **bold** to **tables**

A

acoustic mirrors, 1
acute necrotic collections (ANCs), 155–156
acute pancreatitis (AP), 161–162, 184–185, **185**, 242
adenomyomas, 133–134
administration, 38–39
adrenal gland, 20
adrenal metastasis, 99
adult learning theory, 278
afferent limb syndrome (ALS), 257–258
AIP. *see* autoimmune pancreatitis
air bubbles, 12
air-dried smears, 93
air–water interface, 11
AJCC staging. *see* American Joint Committee on Cancer staging
alcohol-fixed slides, 93
Aldrete scoring system, 35
ALS (afferent limb syndrome), 257–258
American Gastroenterological Association, 150, 156
American Joint Committee on Cancer (AJCC) staging, 42
 anal cancer, 214
 colorectal cancer, 208
 of esophageal cancer, 105, **106**, 108–110
 TNM classification, 114
American Society for Gastrointestinal Endoscopy (ASGE), 31, 32, 38, 52, 103, 275
ampullary adenomas, 120
ampullary adenomyomas, 133
ampullary biopsies, 176
ampullary cancer, 121, 121–123, **122**, 280
ampullary lesions, 123
ampullary tumors, 64
anal cancer, 214
anal sphincter, 214
anatomic orientation, 23
anatomy
 approach to understanding EUS, 24–26
 duodenum, 21
 esophageal radial array, 16
 linear endosonographic, 53
 regional, 15–24
 stomach, 19
ancillary procedures, 38
ANCs (acute necrotic collections), 155–156
aneurysm, Doppler waveform of, 47
antegrade technique, 235, 236
antibiotics, 32
anticoagulants, 42
antitumor agents, 223–225
aorta, 16, 20, 20
AP (acute pancreatitis), 161–162, 184–185, **185**, 242

artifacts, 11
 attenuation, 11–12
 Doppler, 13
 mirror-image, 11
 side-lobe, 12–13
artificial intelligence (AI), 200, 290
ascites, 119–120, 197, 198
ASGE (American Society for Gastrointestinal Endoscopy), 31, 32, 38, 52, 103, 275
aspirate biopsy, 91–92
aspirin, 81
asymptomatic lesions, 129
Atlanta Criteria, 242
attenuation, 7–8
 by air bubbles, 12
 artifacts, 11–12
atypical epithelial cells, 94
audible sound, frequencies of, 6
autoimmune pancreatitis (AIP), 172
 characteristics of, **173**
 classification, 172
 clinical presentation, 172
 diagnosis, 172–176
 EUS imaging features, 176–179
 pancreatic cancer, 173
 treatment and outcomes, 179–180

B

bacteremia, 87
balloons, use of, 2
Barrett esophagus, 62
BBB (blood–brain barrier), 35
beat frequency, 10
benign disorders, 111–114
benign lesions, 120–123
benign lymphadenopathy, 47
benzodiazepines, 34, 35
bile duct strictures, 64
bile peritonitis, 33, 88
biliary access
 equipments, 234
 EUS-guided, 34, 234–239
 indications, 234–235
 outcome, 237–239
 technique, 235–237
biliary adenomas, 203
biliary diseases
 acute biliary pancreatitis, 184–185
 bile duct stones, 183–184
 EUS-guided biliary drainage, 189–191
 EUS-guided gallbladder drainage, 191–193
 indeterminate biliary strictures, 185–189
bilobar sampling, 199
biopsy
 ampullary, 176
 aspirate, 91–92
 autoimmune pancreatitis, 174, 175

core, 91–92
deep, 136
forceps, 135
forward-viewing endoscope for, 127
microscopic evaluation of, 91
needle size, 92
slide preparation and staining, 92–93
snare, 118
suction, 92
technical quality of, 91
types, 91
virtual, 200
bispectral index monitoring, 35
“bite-on-bite” biopsy technique, 112, 129, 135
bleeding, 33
 esophageal varices, 268
 gastric variceal, 268–269, 270
 variceal, 268–269
blood–brain barrier (BBB), 35
brachytherapy, 228
bronchogenic cysts, 98
brush cytology, 92
bulky N2 disease, 99

C

cancer, 188
 anal, 214
 antitumor therapy, 223–225
 treatment, 223–230
candidal infection, 32
capnography, 35
carcinoembryonic antigen (CEA), 150–151
carcinoid tumors, 129–130, 130, 135
casing, 10
catheter probe systems, 28
CCA (cholangiocarcinomas), 64, 203
CCHIT (Certification Commission for Health Information Technology), 40
CCK (cholecystokinin), 245
CDS (choledochoduodenostomy), 236, **238**
CEA (carcinoembryonic antigen), 150–151
CE-EUS (contrast-enhanced endoscopic ultrasonography), 10, 141, 143–144, 144, 146, 167–168, 178, 212
CEH EUS (contrast-enhanced harmonic EUS), 133, 287–288, 288
celiac ganglia neurolysis (CGN), 229, 230
celiac neurolysis (CN), 228–230, 229, **229**, 229
celiac plexus blockade (CPB), 33–34
celiac plexus neurolysis (CPN), 33–34, 55, 223, 230
celiac trunk, 43
cell block, 92
Certification Commission for Health Information Technology (CCHIT), 40
CGN (celiac ganglia neurolysis), 229, 230
chemoradiation therapy, 213–214

- chest
 - major vessels of, 16
 - vascular structures of, 18
- cholangiocarcinomas (CCA), 64, 203
- cholangiograms, 122
- cholangiography, 203
- cholecystokinin (CCK), 245
- choledochoduodenostomy (CDS), 236, **238**
- choledocholithiasis, 64, 183–185
- chronic pancreatitis (CP), 43, 64, 71, 73, 74–75, 75, 162–168
 - diagnostic tool for, 165
 - EUS-guided tissue sampling for, 167
 - modalities in diagnosis of, 165–167, **166**
 - and pancreatic cancer, 167
 - and reproducibility, 163–164
 - Rosemont criteria for, 164, **164**
 - using radial endosonography, 166
- circumferential resection margin (CRM), 211
- cirrhosis, 197–198, 198, 199, 200
- CLA (curvilinear array echoendoscope), 27, 101, *101*, 234, 261
- clinical care, 38
- Clinical Outcomes Research Initiative (CORI)
 - database, 40
- clinical research, 38
- CN (celiac neurolysis), 228–230, 229, **229**, 229
- coccyx, 23
- colonic lymphangiomas, 215
- colonoscopy, 128
- color Doppler, 10, 57
- commercial software product, 41, **41**
- common bile duct stones, 59, 63, 183–184, **184**, 235, 236
- complicated pancreatitis, 242
- computed tomography (CT), 15
 - AIP tests in, 173–175
 - comparison of, 19
 - and EUS, 100
 - EUS images and, 25
 - and magnetic resonance imaging, 127, 211–212
 - thoracic transaxial, 17
 - and transabdominal ultrasonography, 167
- confocal laser endomicroscopy, 152, 288, 289
- consent process, 32–34
 - bleeding, 33
 - infection, 32
- continuous-wave Doppler, 9–10
- contrast-enhanced endoscopic ultrasonography (CE-EUS), 10, 141, 143–144, *144*, 146, 167–168, 178, 212
- contrast-enhanced harmonic (CEH) EUS, 133, 287–288, 288
- conventional reporting, 40
- conventional vs. EUS-guided endoscopic drainage, 244
- core biopsy, 47, 91–92
- CORI database. *see* Clinical Outcomes Research Initiative database
- cost, 103
- CP. *see* chronic pancreatitis
- CPB (celiac plexus blockade), 33–34
- CPN (celiac plexus neurolysis), 33–34, 55, 223, 230
- CRM (circumferential resection margin), 211
- Crohn's disease, 77, 217
- CT. *see* computed tomography
- curiosity, 277
- curvilinear array (CLA) echoendoscope, 27, 101, *101*, 234, 261
- cyanoacrylate, 269
- cystadenoma, 202
- cyst fluid analysis, 150–152
- cystic liver lesions, 202, 202–203
- cysts, 8
 - bronchogenic, 98
 - duplication, 131
 - heterogeneous, 98
 - mediastinal, 49, 98–99
 - pancreatic. *see* pancreatic cysts
 - perirectal, 32
- D**
- databases, 40–41
 - spreadsheet, 39
- deep biopsy, 133, 136
- DEN (direct endoscopic necrosectomy), 245
- descending aorta, 53, 54, 101
- DIA (digital image analysis), 168
- diazepam, 34
- DICOM (Digital Imaging and Communications in Medicine standards), 39
- Dieulafoy lesion, 268
- diffuse large B-cell-type non-Hodgkin lymphoma, 118
- diffuse-type gastric cancer, 118
- DifQuik TM, 93
- digital image analysis (DIA), 168
- Digital Imaging and Communications in Medicine (DICOM) standards, 39
- digital rectal examination, 208
- diphenhydramine, 35
- direct endoscopic necrosectomy (DEN), 245
- direct visualization, 128
- distant lymphadenopathy, 43
- doggedly enthusiastic, 1
- Doppler artifacts, 13
- Doppler imaging, 9–10
 - aneurysm, 47
- Doppler shift, 9–10, 13
- Doppler signal, 10
- droperidol, 35
- dual sampling, 92
- “dumbbell-shaped” masses, 127
- duodenal adenoma, *120*, 120–121, *121*
- duodenal adenomyomatosis, 133–134
- duodenal carcinoid tumor, 130, *130*
- duodenal lipoma, 7
- duodenal perforation, 33
- duodenoscopes, 1
- duodenum, 22–23, 24, 25
 - anatomy, *21*
 - benign disorders, 111–114
 - benign lesions of, 120–123
 - endosonography of, 22
 - and extraduodenal spaces, 22–23
 - gastric lymphoma, 118–120
 - linear EUS, 55–59
 - linear view, 58
 - malignant disorders, 114–118
 - proximal part, 23
 - stomach and, 17, 111
 - of subepithelial masses, 128
 - subepithelial masses in, 127
 - submucosal lesions in, 120
- duplex scanning, 10
- duplication cysts, 131, *131*
- E**
- EA-ERCP (enteroscopy-assisted ERCP), 254, 256
- early gastric cancer, 62, 116–117, *117*
- EASIE-R EUS simulator, 282
- EBL (endoscopic band ligation), 132
- EBUS (endobronchial ultrasound), 45, 47, 100
- echoendoscopes, 1, 15, 28
 - available, **28**
 - colorectal cancer, 207–208
 - electronic radial-array, 28
 - linear-array, 28
 - mechanical, sector-scanning, 1
 - prototype, 1
 - radial-array, 27
 - transverse array, 27
- echoendoscope shaft, 53
- echoes, 12
- ECI (endoscopic cyanoacrylate injection), 197–198
- ectopic pancreas, 131
- EDEE (EUS-directed transenteric ERCP), 256–257, 257
- EFTR (endoscopic full thickness resection), 133, 136
- EGJ (esophagogastric junction), 105
- elasticity modulus, 68, 69
- elastography, 38, 68, 144–145, *145*, 167, 288
 - applications, 68, 71
 - basis for, 68
 - chronic pancreatitis, 74–75
 - classification and/or significance, **69**
 - evaluation, 68
 - lymph nodes, 75–77, 76
 - pancreatic diseases, 71–75
 - pattern, 69
 - quantitative strain, 69–70, *70*
 - registration, 69
 - shear wave, 70–71
 - strain, 68–70
 - technical aspects and methodology, 68–71
 - transrectal, 77
- elastogram, 10
- elastography, 10
- electromagnetic waves, 5
- electronic (video) endoscope, 1
- electronic radial echoendoscopes, 28, 111
- electronic vs. handwritten reports, 40
- EMR (endoscopic mucosal resection) therapy, 62, 106, 130, 136
- endobronchial ultrasound (EBUS), 45, 47, 100
- endocrine dysfunction, 172
- endoluminal ultrasound, 216
- endoscopic band ligation (EBL), 132
- endoscopic cyanoacrylate injection (ECI), 197–198
- endoscopic drainage, of PFCs, 243–244
- endoscopic full thickness resection (EFTR), 133, 136
- endoscopic mucosal resection (EMR) therapy, 62, 106, 130, 136
- endoscopic mucosectomy, 136
- endoscopic pancreatic function test (ePFT), 75, 163
- endoscopic reports
 - ASGE recommendations, **39**
 - commercial software for, 41, **41**
 - completeness, 40
 - complications, 42
 - databases, 40–41
 - definition, 38
 - disease-specific information, 42–43
 - evolution of medical report, 39
 - free text and conventional, 40
 - general EUS information in, 42
 - interventions in, 42
 - key elements, 41
 - non-EUS information, 41
 - procedure summary, 42
 - quality, 42
 - role, 38–39
 - speed, 40
 - standard terminology, 39
 - structured reporting, 39–40
- endoscopic retrograde cholangiography (ERC), 175
- endoscopic retrograde cholangiopancreatography (ERCP), 3, 27, 28, 35, 53, 122, 142, 162, 172, 175–176
 - with cholangiocarcinomas, 203
 - and EUS-guided biliary drainage, **191**
 - and secretin-stimulated duodenal aspiration, 166–167

- endoscopic submucosal dissection (ESD), 106, 109, 117, 129, 130, 136
- endoscopic ultrasonography (EUS), 127
- acute pancreatitis, 161–162, 184–185, **185**
 - advantage, 100
 - anatomy, 15
 - aspect, 3
 - assistants, 30–31
 - beginnings of, 1–4
 - biopsy. *see* biopsy
 - chronic pancreatitis, 162–168
 - contrast-enhanced, 143–144, *144*
 - contrast-enhanced harmonic, 133
 - cost, 103
 - and cross-sectional visible human anatomy, 23, 24
 - and CT images, 25
 - of duplication cysts, 131
 - in early NSCLC, 100
 - elastography. *see* elastography
 - ERCP and, 35
 - esophageal cancer. *see* esophageal cancer
 - examination, 42
 - experience levels for, **284**
 - feasibility of, 1
 - fine needle aspiration. *see* fine needle aspiration
 - first International Workshop on, 3
 - future, 287–291
 - general principles, 15
 - high-frequency ultrasound. *see* high-frequency ultrasound probes
 - image enhancement techniques in, 178–179
 - imaging, new techniques in, 10
 - imaging principles and fundamentals, 5–14
 - inception, 1
 - in inflammatory bowel disease, 216–217
 - instruments and other equipment, 27–29
 - instruments types, 290
 - interobserver agreement of, 135
 - interventional, 290, **291**
 - mediastinum. *see* mediastinum
 - for metastatic disease, 102
 - Minimal Standard Terminology system, 39
 - and MS, 100
 - neoadjuvant therapy, 103
 - for pancreatic cysts. *see* pancreatic cysts
 - pancreatic tumors, 141–142
 - in patients with RAP, **162**
 - perforation during, 33
 - phantom images, 282
 - procedures, 32–35
 - rationale for, 99–100
 - rectal cancer. *see* rectal cancer
 - recurrent acute pancreatitis, 162
 - reports. *see* endoscopic reports
 - rescue, 100
 - room setup, 29–30, 30
 - simulator, *281*
 - stack up, 100
 - transesophageal, 98
 - Trucut biopsy, 135–136
 - Users Group, 3
 - using forward-viewing linear echoendoscope, *187*
 - vascular and ductal structures of, 16
- endoscopic ultrasonography-guided biliary drainage (EUS-BD), 32
- endoscopy
- of stromal cell tumors, 132
 - tissue sampling, 135–136
 - video, 127
- endosonographers, 30, 150
- endosonography, 15, 213
- complications, 49–50
 - diagnosis, 47–48
 - of duodenum, 22
- early days of, 1
- EUS/EUS-FNA in, 45–47
- examination, 208
- gratifying aspects, 2
- indications for, 47, **48**
- interventional, 45
- interventional endoscopy, 49
- malignant diseases, 48–49
- of mediastinum, 45–50
- for routine indications, 45
- training in, 52
- viability, 1
- enlarged lymph node, 25
- enteral feeding, 245–247
- enteral stenting vs. surgical gastrojejunostomy, 254, **255**
- enteroscopy-assisted ERCP (EA-ERCP), 254, 256
- eosinophilic esophagitis, 62
- eosinophilic gastroenteritis, 112
- EPASS technique, 252
- ePFT (endoscopic pancreatic function test), 75, 163
- epithelioid hemangioendothelioma, 201
- ERC (endoscopic retrograde cholangiography), 175
- ERCP. *see* endoscopic retrograde cholangiopancreatography
- ESD (endoscopic submucosal dissection), 106, 109, 117, 129, 130, 136
- esophageal cancer, 3, 33, 42–43, **62**
- AJCC staging of, **106**
 - EUS image of, 12, 106
 - limitations, 110
 - local staging of, **280**
 - role of EUS in, 105–110
 - squamous cell cancer, *106, 107*
 - staging guidelines for, 105
 - T-staging accuracy of, 62
- esophageal radial array anatomy, 16
- esophageal varices, 62
- bleeding, 268
- esophagogastric junction (EGJ), 105
- esophagus, 9, 24
- chest and relation to, *18*
 - and extraesophageal spaces, 15–16
 - and gastroesophageal junction, 11
 - linear EUS, 53–54
 - of subepithelial masses, 128
- EUS. *see* endoscopic ultrasonography
- EUS-BD (endoscopic ultrasonography-guided biliary drainage), 32
- EUS-directed transenteric ERCP (EDEE), 256–257, *257*
- EUS FNA. *see* EUS-guided fine-needle aspiration
- EUS-GBD (EUS-guided gallbladder drainage), 191–193, *192*
- EUS-GE (EUS-guided gastroenterostomy), 251–254
- EUS-guided biliary drainage (EUS-BD), 189–191, *190, 191, 237*
- for biliary drainage, **238**
 - left hepatic duct, 235
 - with PTBD, **238**
 - selection, 239
 - training for, 239
- EUS-guided entero-anastomosis (EUS-EA) technique, 251–258
- EUS-guided ERCP approach, 183
- EUS-guided fine-needle aspiration (EUS FNA), 32–33, 47–49, 100, 179
- algorithmic approach to, 83
 - aspirate, 155
 - and cyst fluid analysis, 150–152
 - cytology, 91–95
 - diagnostic sensitivity, 143–144
 - distal common bile duct, *186*
 - equipment and staffing, 82–83
- fundamentals, 81–88
- of gallbladder mass, 189, *189*
 - gene mutation analysis, 143
 - of indeterminate biliary strictures, 185–189, **186**
 - indications and contraindications, 81
 - informed consent, 82
 - laboratory role, 94–95
 - lesion characteristics, 85
 - mediastinum. *see* mediastinum
 - needle size, 85
 - onsite cytopathology, 86–87
 - pancreatic tumors, 142–143
 - portal hilar lymph node, 82
 - post-procedural fundamentals, 87
 - procedural goals, 81–82
 - prophylactic antibiotics, 82
 - safety, 87–88
 - stylet during, 85
 - target lesion, 83–84
 - techniques, 84–85, 88, 156–157
 - training, 83
 - use of suction during, 85
- EUS-guided gallbladder drainage (EUS-GBD), 191–193, *192*
- EUS-guided gastroenterostomy (EUS-GE), 251–254
- enteral stenting vs. surgical gastrojejunostomy, 254, **255**
 - gastric outlet obstruction, 251–252
 - technical aspects and clinical outcomes, 252–253
- EUS-guided liver biopsy (EUS-LB), 28, 198–199, **199**
- EUS-guided portal pressure gradient measurement (EUS-PPG), 199–200, **200**
- EUS-guided sampling, 68, 73, 135
- EUS-LB (EUS-guided liver biopsy), 28, 198–199, **199**
- EUS-PPG (EUS-guided portal pressure gradient measurement), 199–200, **200**
- exocrine dysfunction, 172
- extraduodenal spaces, 22–23
- extraesophageal spaces, 15–16
- extragastric spaces, 16–22
- extrahepatic approach, 235
- extraluminal bleeding, 87
- extrarectosigmoid spaces, 23–24
- extrinsic compression lesions, 134
- F**
- failed bronchoscopy, 100
- false-negative Doppler signals, 13
- FCSEMS (fully covered self-expanding metal stents), 236, 237, 244
- female rectum, 59
- fentanyl, 34–35
- fiberoptics, 1
- fibrolamellar HCC, 201
- fibrotic liver parenchyma, *198*
- fibrotic transformation, 197
- fiducial marker placement, 226–228, *227*
- field-independent, 277
- fine needle aspiration (FNA), 28, 30, 31, 38, 47–49, 101–102, 116, 129, 288–290. *see also* EUS-guided fine-needle aspiration
- colorectal cancer, 211
 - deep mucosal biopsies and, 133
 - of liver metastases, 83
 - lymph nodes for, 101
 - needle-track seeding, 33, 47
 - pancreatic cyst, 86, 87, 87
 - perirectal lymph node, *211, 212*
 - portal hilar lymph node, 82
 - subcarinal lymph node, 82
 - training, 275
- fine needle biopsy (FNB), 28, 30, 31, 88, 288–290
- cyst wall, 152
 - EUS-guided FNA to, 135–136

fine-needle injection (FNI), 275
 flexible sigmoidoscopy, 128
 FLLs (focal liver lesions), 197
 fluid-filled structures, 15
 flumazenil, 34
 FNA. *see* fine needle aspiration
 FNB. *see* fine needle biopsy
 FNH (focal nodular hyperplasia), 202
 FNI (fine-needle injection), 275
 focal liver lesions (FLLs), 197
 focal nodular hyperplasia (FNH), 202
 foregut carcinoids, 129
 foregut duplication cysts, 98
 forward-viewing curvilinear echoendoscopes, 127, 208
 freehand technique, 252
 free text, 40
 frequency dependence, 8
 Fujinon Company, 27, 28, **28**, **29**
 fully covered self-expanding metal stents (FCSEMS), 236, 237, 244

G

GABA-A receptor blocker, 34, 35
 gallbladder polyps, 188, **188**
 gallbladder wall, 178
 gangliocytic paragangliomas, 133
 gastric cancer, 42–43, *116*
 diffuse-type, 118
 distant metastasis, **114**
 early, 62, 116–117, *117*, *118*
 incidence of, 114
 intestinal-type, 114–116
 malignant disorders, 114
 primary tumor staging, **114**
 regional lymph nodes staging, **114**
 T and N stages of, **280**
 gastric folds, 111
 gastric lipomas, 129, *129*
 gastric lymphoma, 118–120
 gastric outlet obstruction (GOO), 251–254
 Gastric Outlet Obstruction Scoring System (GOOSS), 252, **253**
 gastric variceal bleeding, 268–269, *270*
 gastric varices, 113, *115*, 131, *131*, 131–132
 gastric wall
 thickness, *112*
 wall structure of, 63
 gastroesophageal (GE) junction, 11, 54
 gastrointestinal subepithelial masses. *see* subepithelial masses
 gastrointestinal (GI) tract wall, 8–9
 layers, 9
 GE (gastroesophageal junction), 11, 54
 GEL (granulocyte epithelial lesion), 173
 gemcitabine, 224
 GF-UM2 echoendoscope, 4
 glycoproteins, 150
 GNAS mutations, 151, 152, 154
 GOO (gastric outlet obstruction), 251–254
 GOOSS (Gastric Outlet Obstruction Scoring System), 252, **253**
 granular cell tumor, of stomach, 130, *130*
 granulocyte epithelial lesion (GEL), 173
 gut wall, structured image of, 2

H

“hands-on” instruction, 3
 handwritten reports, 39
 HCC (hepatocellular carcinoma), 198, 200–201
Helicobacter pylori gastritis, 111, 118
 hemangiomas, 202
 hemangiosarcoma, 201
 hemostasis, 267–271

nonvariceal GI bleeding, 267–268
 of pseudoaneurysms, 269–271, *271*
 of variceal bleeding, 268–269
 heparin, 92
 hepatic adenomas, 201–202
 hepaticogastrostomy, **238**
 hepatic parenchyma, 197
 hepatic steatosis, 198, *199*
 hepatocellular carcinoma (HCC), 198, 200–201
 hertz (Hz), 5
 heterogeneous cysts, 98
 heterotopic pancreas, 131
 HFUS probes. *see* high-frequency ultrasound probes
 hierarchical model, 40
 high-frequency ultrasound (HFUS) probes, 5, 61, **62**, *62*
 anatomical correlation, 61–62
 applications, 62
 in esophageal carcinoma staging, **62**
 esophagus, 62
 of pancreas, *64*
 small bowel and colon, 63
 stomach, 62–63
 technical features, 61
 3D imaging, *65*
 T-staging accuracy of, 62
 hindgut carcinoids, 129
 hospital privileges, 283–284
 hypertrophic gastropathies, 112–113, *115*
 hypoechoic lesion, 177

I

ICCs (interstitial cells of Cajal), 132
 IDCP (idiopathic duct-centric pancreatitis), 172
 idiopathic duct-centric pancreatitis (IDCP), 172, 173
 IDUS. *see* intraductal ultrasonography
 IgG₄-sclerosing cholangitis (IgG₄-SC), 175, 176, *177*, *178*
 IHBT (intrahepatic biliary tract), 239
 indeterminate biliary strictures, 185–189
 inferior vena cava, 53
 infiltrative gastric cancer, 111
 inflammatory bowel disease, 63, 216–217
 informed consent, 82
 interface echoes. *see* specular reflectors
 Internet resources, 283
 interpretation quality, 94
 interstitial cells of Cajal (ICCs), 132
 interventional endoscopy, 49
 interventional endosonography, 45
 intestinal-type gastric cancer, 114–116
 intraductal papillary mucinous neoplasm (IPMN), 87, 150, 153
 intraductal ultrasonography (IDUS), 28, 122–123, 166, 176
 anatomical correlation, 63–64
 applications, 64
 complications, 64
 development, 63
 radiologic images of, 63
 technical features, 63
 3D imaging, *65*
 intrahepatic approach, 235
 intrahepatic biliary disorders, 203
 intrahepatic biliary tract (IHBT), 239
 intrahepatic cholangiocarcinoma, 203
 intraluminal recurrence, 213
 intravenous injection, 10
 IPMN (intraductal papillary mucinous neoplasm), 87, 150, 153

K

Kappa scores, 150
 ketamine, 35

KIT protein, 132
 Kolb's experiential learning model, 278
 K-Ras gene mutation analysis, 143
 KRAS mutations, 151–152, 154

L

LA-ERCP (laparoscopy-assisted ERCP), 254, 256
 LAMS. *see* lumen-apposing metal stents
 laparoscopy-assisted ERCP (LA-ERCP), 254, 256
 laser ablation, 226
 learning EUS, 276–283
 LECs (lymphoepithelial cysts), 155, *155*
 legal issues, 38–39
 leiomyomas, 77, 129, 132–133
 lesions, 83, *102*, *107–109*, 128
 ampullary, 121–123
 characteristics, 85
 cystic liver, *202*, *202–203*
 extrinsic compression, 134
 myogenic, 215
 pancreatic cysts, 43, **151**, 152–157
 perigastric/periduodenal, 113–114
 target, 83–84
 linear-array EUS, 27, 28, 45, 52–59, 101, 207, 287
 duodenum, 55–59
 esophagus, 53–54
 examination, 52–53
 fluoroscopic views of, 57
 home base structures for, **53**
 stomach, 54–55, 55
 linitis plastica, of rectum, 63, 114, 118, 214
 lipomas, 7, 129, 214
 liquid-based cytology, 93
 liver disease
 benign lesions in, 201–202
 biliary adenomas, 203
 cystic, 202–203
 emerging imaging techniques, 200
 EUS-guided liver biopsy, 198–199
 EUS-PPG, 199–200, **200**
 imaging technique, 197
 intrahepatic biliary disorders, 203
 liver parenchymal abnormalities, 197–200
 malignant lesions in, 200–201
 liver metastases, 83, 201, *201*
 liver parenchymal abnormalities, 197–200
 live swine model, 281
 LN. *see* lymph nodes
 lumen-apposing metal stents (LAMS), 4, 114, 189, 193, 244, 251, **252**
 cystgastrostomy, *244*
 distal flange of, *243*
 misdeployments, 254
 pancreatic fluid collections, 243
 pelvic fluid collections, 261–262
 luminal cancer, 42–43
 lung cancer, 48
 mediastinal staging, 98–99
 thoracic nodal groups used in, *54*
 lymph nodes (LN), 20, 45, 75–77, *76*
 differential diagnosis of, **77**
 for fine needle aspiration, 101
 malignant, *117*, *209*
 metastases, **280**
 Mountain and Dresler regional, 99
 N-stage, 209
 posterior mediastinal, *135*
 qualitative EUS elastography of, 76
 quantitative EUS elastography of, 76
 lymphoepithelial cysts (LECs), 155, *155*
 lymphoma, 63, 118
 Ann Arbor classification for, **119**
 lymphoplasmacytic sclerosing pancreatitis (LPSP), 172, **173**, *174*

M

MAC (monitored anesthesia care), 34
 machine learning algorithms, 157
 macroscopic on-site evaluation (MOSE), 88, 290
 magnetic resonance cholangiopancreatography (MRCP), 162, 163, 167, 172, 176, 203
 magnetic resonance imaging (MRI), 127, 173–175, 211–212. *see also* computed tomography
 magnetic resonance pancreatography (MRP), 175
 male rectum, 59
 malignant disorders, 48–49, 114–118
 malignant lymph nodes, 115, 117
 MALT (mucosa-associated lymphoid tissue), 118
 MALT lymphoma, 118
 Mayo Clinic protocol, 187
 MCN (mucinous cystic neoplasms), 150
 “mechanical, sector-scanning echoendoscope,” 1
 mediastinal cysts, 49, 98–99
 mediastinal foregut cyst, 32
 mediastinal lymph nodes, 45
 mediastinum, 16
 applications in, 98–103
 endobronchial ultrasonography, 100
 endoscopic ultrasonography, 98
 endosonography of, 45–50
 examination, 101
 failed bronchoscopy and EUS rescue, 100
 medical mediastinoscopy, 100
 metastatic disease, 102–103
 neoadjuvant therapy, 103
 primary lung lesions, 102
 training, 103
 medical report, evolution of, 39
 melanoma, 102
 menetrier gastropathy, 63
 Menetrier’s disease, 112–113
 meperidine, 34
 metastatic liver disease, 98, 102, 201, 201
 midazolam, 34
 midgut carcinoids, 129
 Minimal Standard Terminology (MST) system, 39–40, 163
 miniproboscopes, 207–208
 mirror-image artifact, 11
 molecular analysis, of aspirated cells, 94
 monitored anesthesia care (MAC), 34
 monitoring
 bispectral index, 35
 of patient, 87
 post-procedural, 35
 procedural, 35
 MOSE (macroscopic on-site evaluation), 88, 290
 motivation, for self-study, 276–277
 MRCP (magnetic resonance cholangiopancreatography), 162, 163, 167, 172, 176, 203
 MRP (magnetic resonance pancreatography), 175
 mucinous cystic neoplasms (MCN), 150
 mucin-producing tumors, 64
 mucosa-associated lymphoid tissue (MALT), 118
 mucosal cysts, 129
 mucosal polyps, 129
 muscularis mucosa, 9, 215
 muscularis propria (MP), 107, 108, 209
 myogenic tumor, 215

N

naloxone, 35
 National Comprehensive Cancer Network (NCCN), 99, 130
 National Endoscopy Database, 40
 National Voluntary Laboratory Accreditation Program (NVLAP), 40

NCCN (National Comprehensive Cancer Network), 99, 130
 needle aspiration, 1
 needle track implantation, of malignant cells, 33
 neoadjuvant chemoradiation, 213
 neoadjuvant therapy, 4, 103, 109, 213
 neoplastic cysts, 150
 network model, 40
 neutrophils, 175
 Next Generation Sequencing (NGS) techniques, 151–152
 N-methyl D-aspartate (NMDA) receptor, 35
 non-alcoholic fatty liver disease (NAFLD), 198
 nonhealing gastric ulcer, 113
 noninvasive mucinous cystic neoplasms (MCN), 202
 nonneoplastic cyst, 150, 155
 non-small-cell lung carcinoma (NSCLC), 98
 EUS in early, 100
 precise mediastinal staging, 99
 nonspecular reflectors, 8–9
 nonsteroidal anti-inflammatory drug (NSAID), 113
 nonvariceal GI bleeding, 267–268
 NSCLC. *see* non-small-cell lung carcinoma
 N-staging, 209, 210
 rectal cancer, 210
 NVLAP (National Voluntary Laboratory Accreditation Program), 40

O

Olympus Optical Company, 1, 27, 28, 28, 29
 OMED (Organization Mundial D’Endoscopie Digestif), 39
 OncoGel, 224
 ONYX-015, 223
 opiates, 34–35
 Organization Mundial D’Endoscopie Digestif (OMED), 39
 overlying mucosa, 136

P

pancreas
 acute pancreatitis, 161–162
 chronic pancreatitis, 162–168
 EUS imaging of, 176–178
 recurrent acute pancreatitis, 162, 162
 transduodenal imaging of, 162
 using radial endosonography, 163
 pancreatic adenocarcinoma, 64
 pancreatic cancer (PC), 71
 autoimmune pancreatitis, 173
 chronic pancreatitis and, 167
 contrast-enhanced EUS, 143–144, 144
 diagnosis and staging of, 141–146
 elastography, 144–145, 145
 endoscopic ultrasonography, 141–142
 EUS-FNA, 142, 142–143
 irregular mass in, 142
 staging with different techniques, 145–146
 pancreatic cysts, 13, 98
 characteristics, 152–157, 153
 classification, 150
 EUS morphology, 150
 fluid analysis, 93–94
 FNA of, 87, 87
 lesions, 43, 151
 neoplasms, 150, 152–156
 nonneoplastic, 150, 155
 serous neoplasms, 154–155
 solid pseudopapillary neoplasms, 155
 solid tumors as, 156
 pancreatic diseases, 71–75
 pancreatic duct stone, 12, 162
 pancreatic fluid collections (PFCs), 242
 classification, 242
 enteral feeding, 245–247
 multidisciplinary algorithm for, 247
 pancreatic ductal evaluation, 247
 tailored multidisciplinary approach, 247
 treatment, 242–245
 walled-off pancreatic necrosis, 245, 246
 pancreatic neuroendocrine tumors (PanNETs), 152
 pancreatocolithiasis, 164
 pancreatic pseudocyst, 135
 pancreatic rest, 131
 pancreatic strictures, 64
 pancreatitis, 33, 43
 pancreatograms, 122
 PANDA study, 151
 PANTER trial, 245
 Papanicolaou Society of Cytopathology, 94
 Papanicolaou (Pap) stains, 93
 parallel enteric tube (PET) method, 252
 PC. *see* pancreatic cancer
 PCGW (physician-controlled guidewire manipulation), 239
 pelvic abscess drainage, 264, 265
 pelvic endometriosis, 216
 pelvic fluid collections, 262, 263
 CT images of, 264
 evidence, 263–264
 patient preparation, 261
 pelvic abscess drainage, 264, 265
 post-procedure care and follow-up, 262–263
 technical and clinical tips, 264–265
 pelvic malignancies, 217–218
 Pentax Company, 27, 28, 28
 perceptual learning, 277
 percutaneous drainage, of PFCs, 243
 percutaneous gallbladder drainage (PT-GBD), 191
 percutaneous transhepatic biliary drainage (PTBD), 234, 239
 perforation, 2, 33
 perigastric/periduodenal lesions, 113–114
 perirectal abscesses, EUS-guided drainage of, 217
 perirectal cyst, 32
 PET (parallel enteric tube) method, 252
 PFCs. *see* pancreatic fluid collections
 photodynamic therapy (PDT), 225–226
 physician-controlled guidewire manipulation (PCGW), 239
 piezoelectric crystals, 5, 15, 28
 pigtail plastic stent, 236
 plastic casing, 10
 plastic double pigtail stents, 244
 platelet-derived growth factor (PDGFRA), 132
 polypoid morphology, 211
 porta hepatis, 55
 portal hypertension assessments, 197–198
 portal vein thrombosis (PVT), 23, 201
 posterior mediastinal lymph nodes, 135
 post-procedural monitoring, 35
 power Doppler, 10
 primary gastric lymphoma, 119
 primary liver lymphoma, 201
 primary lung lesions, 102
 primary sclerosing cholangitis (PSC), 203
 procedural monitoring, 35
 promethazine, 35
 prophylactic antibiotics, 82, 98, 261
 propofol, 35
 prototype echoendoscope, 1
 “pseudocysts,” 155
 PTBD (percutaneous transhepatic biliary drainage), 234, 239
 PT-GBD (percutaneous gallbladder drainage), 191
 pulsed Doppler, 9–10
 pulse-wave analysis, 57
 PVT (portal vein thrombosis), 23, 201

Q

qualitative strain elastography, 68–69, 69
 quality
 control, 38
 of EUS reports, 42
 interpretation, 94
 quantitative strain elastography, 69–70, 70
 “quick and dirty” approach, 3

R

radial-array echoendoscope, 27, 45, 101, 105, 207, 234, 287
 radial endosonography, 163
 radial EUS, 101
 radiation therapy, 214
 radiofrequency ablation (RFA), 225–226
 RAP (recurrent acute pancreatitis), 162, **162**
 rapid onsite cytologic evaluation, 94
 rapid onsite evaluation (ROSE), 28, 29, 30, 86, 88
 rectal/colorectal cancer, 42–43, 63, 209
 carcinoid tumors, 130
 clinical impact of, 212–213
 contrast-enhanced EUS for, 212
 CT and MRI comparison, 211–212
 examination technique, 208
 fine-needle aspiration, 211
 instruments for, 207–208
 interobserver variability in, 211
 local recurrence of, 213
 local staging of, **280**
 N-staging accuracy, 210
 radial EUS image, 209
 rectosigmoid and pelvic endometriosis, 216
 staging by EUS, 208–209
 three-dimensional EUS for, 212
 T-staging accuracy, 209–210
 rectal endosonography, 128
 rectal variceal bleeding, 269
 rectosigmoid, 216
 rectosigmoid colon, 129
 rectum
 carcinoid tumors of, 215
 and extrarectosigmoid spaces, 23–24
 linitis plastica of, 214
 subepithelial bulge in, 215
 of subepithelial masses, 128–129
 recurrent acute pancreatitis (RAP), 162, **162**
 ReGel, 224
 regional anatomy, 15–24
 duodenum and extraduodenal spaces, 22–23
 esophagus and extraesophageal spaces, 15–16
 rectum and extrarectosigmoid spaces, 23–24
 stomach and extragastric spaces, 16–22
 region of interest (ROI), 69, 71
 relational model, 40–41
 renal cell carcinoma metastasis, 102
 rendezvous technique, 235
 resolution cell, 7
 “retract–ligate–unroof–biopsy” technique, 136
 RFA (radiofrequency ablation), 225–226
 rituximab, 180
 ROSE (rapid onsite evaluation), 28, 29, 30, 86, 88
 Rosemont Criteria, 43
 Rosemont criteria, for chronic pancreatitis, 164, **164**
 RPMI-1640, 93

S

sacrum, 23
 SCAs (serous cystadenomas), 152, 154, 154
 scatterers. *see* nonspecular reflectors
 Schwannoma, 77
 “seagull” adrenal gland, 101
 sedation, 34–35
 pre-procedure assessment, 34

SELs (subepithelial lesions), 43, 214–216
 sequential sampling, 92
 serosa, 115
 serous cystadenomas (SCAs), 152, 154, 154
 serous neoplasms, 154–155
 shear wave elastography, 70–71, 71, 75, 167
 shear-wave velocity (Vs), 70–71
 side-lobe artifacts, 12–13
 “slow pull” method, 28
 small hyperechoic liver hemangioma, 202
 smears, 91
 snare biopsy, 118
 SNOMED (Systematized Nomenclature of Medicine), 39, 41
 soft tissue, 5, 12
 solid liver lesion, 78
 solid pancreatic lesions, 71–74
 accuracy, 74
 qualitative EUS elastography of, 72
 quantitative EUS elastography of, 72, 73
 solid pancreatic tumors, 43
 solid pseudopapillary neoplasms (SPN), 155
 solid tumors, as pancreatic cysts, 156
 Sonazoid, 144
 SonoVue, 144
 sound waves, 5–6
 specular reflectors, 8–9, 12
 spleen, 20
 splenic vein, 20, 55
 spray fixative, 92
 spreadsheet database, 39
 squamous cell cancer, 107, 110
 squamous cell carcinoma, 214
 steatosis, 198
 steroid trial, 173
 stomach, 11
 anatomy, 19
 benign disorders, 111–114
 and duodenum, 111
 endoscopic appearance of, 112
 endosonographic stations in, 55
 and extragastric spaces, 16–22
 gastric lymphoma, 118–120
 granular cell tumor of, 130
 home base view for, 56
 linear EUS, 54–55, 55
 malignant disorders, 114–118
 pancreatic pseudocyst against, 135
 stromal cell tumor of, 132
 of subepithelial masses, 128
 strain elastography, 68–70, 167
 qualitative, 68–69, 69
 strain histogramis, 69
 strain ratio, 69–70, 73, 74, 74
 quantitative elastography using, 77
 strain ratio analysis, 70
 streptococcal sepsis, 32
 stromal cell tumors, 132, 132–133, 133, 134
 structured reporting, 40
 subcarinal lymph node, 46
 subepithelial lesions (SELs), 43, 214–216
 subepithelial masses
 comparison of imaging studies in, 134
 differential diagnosis of, **128**
 endoscopic findings, 127
 endoscopic tissue sampling, 135–136
 extrinsic compression lesions, 134
 in gastrointestinal (GI) tract, 127
 imaging techniques, 127–128
 management in, 134–135
 mucosal layer, lesions in, 129
 muscularis propria, lesions in, 132–134
 submucosa, lesions in, 129–132

submucosa, 8, 9
 lesions in, 129
 submucosal lesions, 127
 submucosal tunneling endoscopic resection (STER), 133, 136
 “suck–ligate–unroof–biopsy” technique, 136
 suction, 92
 surgical drainage of PFCs, 243
 surgical necrosectomy, 245
 symptomatic cysts, 150
 Systematized Nomenclature of Medicine (SNOMED), 39, 41

T

tailored multidisciplinary approach, 247
 tangential scanning, 11, 12
 target lesion, 83–84
 T4 disease, 102
 telecytology, 29
 telemedicine, 283
 therapeutic EUS, 114
 thoracic transaxial CT, 17
 3-dimensional finite element model, 68
 through-the-needle biopsy (TTNB) technique, 152, 290
 thyroid lesions, 49
 time gain compensation (TGC), 7
 time-varying gain (TVG) compensation, 8
 tissue harmonic echo (THE), 287
 tissue movement detection, 9–10
 tissue penetration, 7–8
 tissue reflector, types of, 8–9
 TJLB (transjugular liver biopsy), 198
 TNFerade, 223, 224
 training
 in endosonography, 52
 EUS FNA, 83
 hospital privileges, 283–284
 learning, 276–283
 mediastinum, 103
 options, 275–276
 quality indicators in, 276
 terminology, 283
 without fellowship, 283
 transabdominal ultrasonography (TUS), 161, 167, 197, 276
 transanal endoscopic microsurgery (TEM), 210
 transaortic FNA, 48
 transducers, 1, 5, 6, 10, 15
 mirror image (m) of, 11
 properties affecting images, 6–7
 size and lateral resolution, 7
 US frequency on beam pattern of, 7
 transduodenal guidewire, 236
 transesophageal endoscopic ultrasonography, 98
 transjugular liver biopsy (TJLB), 198
 transmural technique, 235, 236
 transrectal EUS elastography, 77
 transverse array echoendoscope, 27
 Trucut biopsy (TCB) needle, 42, 102, 135
 sensitivity and safety of, 179
 T-staging, 211
 accuracy, 62
 for rectal cancer, 209–210
 TTNB (through-the-needle biopsy) technique, 152, 290
 tumoral stenosis, 211
 tumor–node–metastases (TNM) system, 42, 48, 100
 tumors. *see also* specific types
 carcinoid, 129–130, 130, 135
 esophageal, 2
 pancreatic, 141–143
 stromal cell, 132, 132–133, 133, 134

“tunneling” biopsy technique, 135
 TUS (transabdominal ultrasonography), 161, 167, 197, 276
 type 1 AIP. *see* lymphoplasmacytic sclerosing pancreatitis
 type 2 AIP. *see* idiopathic duct-centric pancreatitis

U

UCA (US contrast agent), 10
 ulcerative colitis (UC), 217
 ultrasound (US)
 basic image types, 6
 on beam pattern of transducer, 7
 catheter probes, **29**
 frequency, 6, 7
 frequency on axial resolution, 6, 7, 7
 images, 5
 intra-ductal, 28

principles, **13**, 52
 transducers, 5, 10, 11
 waves, 5–6, 11
 uncomplicated pancreatitis, 242
 US. *see* ultrasound
 US contrast agent (UCA), 10
 Users Group, 3

V

VARD (videoscopic-assisted retroperitoneal debridement), 243, 245
 variceal bleeding, 268–269
 varices. *see* gastric varices
 vascular endothelial growth factor receptor (VEGFR), 210
 vascular pulsation, 10
 VEGFR (vascular endothelial growth factor receptor), 210

VHL mutation, 154
 video endoscopy, 127
 videoscopic-assisted retroperitoneal debridement (VARD), 243, 245
 virtual biopsy, 200
 visual perception and reality, 277

W

walled-off necroses (WONs), 155–156
 walled-off pancreatic necrosis (WOPN), 245, **246**
 water-filled stomach technique, 127
 WONs (walled-off necroses), 155–156
 WOPN (walled-off pancreatic necrosis), 245, **246**

Y

Young's modulus, 70

